糖原合成酶1向揭示了三阴性乳腺癌的代谢脆弱性
E C de Heer1, C E Zois2,3,4, E Bridges5
1Department of Medical Oncology, University of Groningen, University Medical Center Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.
概括
糖原合成酶1 (GYS1) 在侵袭性乳腺癌中被上调,导致扩散和耐治疗性. 抑制GYS1可能为三阴性乳腺癌 (TNBC) 提供一种新的治疗策略.
科学领域:
- 生物化学和分子生物学
- 癌症研究 癌症研究
- 癌症中的代谢途径
背景情况:
- 低氧驱动的糖原代谢推动了癌症的生长和抗治疗能力.
- 三阴性乳腺癌 (TNBC) 呈现出低氧微环境和治疗反应差.
- 糖原合成酶1 (GYS1) 是糖生成中的一个关键酶,调节糖原合成.
研究的目的:
- 为了研究乳腺癌患者瘤中的GYS1表达.
- 评估GYS1表达和患者存活率之间的相关性.
- 在临床前模型中确定GYS1下调对乳腺癌进展和药物敏感性的影响.
主要方法:
- 来自METABRIC数据集 (n=1904) 的GYS1mRNA表达和患者生存数据的分析.
- 在原发性乳腺瘤中对GYS1和糖原的免疫组织化学评估 (n=337).
- 在乳腺癌细胞系中使用RNA干扰和TNBC异种移植模型来评估扩散,糖原水平和药物敏感性.
主要成果:
- 高GYS1mRNA表达与降低患者整体存活率相关,特别是在TNBC中.
- 在TNBC和Ki67高的瘤中,GYS1蛋白表达显著升高.
- GYS1 knockdown 抑制了乳腺癌细胞的增殖,耗尽了糖原储存,减缓了异体移植瘤的生长,并增加了对线粒体蛋白质稳定抑制剂的敏感性.
结论:
- GYS1是乳腺癌的潜在治疗标,特别是在TNBC和高度增殖的亚型.
- 向GYS1可能会克服与缺氧和瘤生物学相关的治疗阻力.
更多相关视频
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
13.1K
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
11.4K
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
